MBOT
Q3 2026 EPS Estimate
$-0.08
Aug 11, 2026 · Reports before open
Revenue Estimate
$333,333
FY2029E EPS$0.03

Analyst Sentiment

Wall St. Consensus
Buy
3 analysts·Low coverage
67
Score
2 Buy (67%)1 Hold (33%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
267%
Hold
133%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$4.00
+128.6%
Consensus
$4.00
+128.6%
Bull
$4.00
+128.6%
12-Month Target Range3 analysts
$4.00$4.00$4.00
Current $1.75Consensus
Current Price
$1.75
Upside to Consensus
$2.25

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+215.04%
EPS
FY2028
Rev+169.66%
EPS
FY2029
Rev+98.33%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$3M$9M$24M$48M
Low$2M$6M$20M$40M
High$4M$12M$28M$55M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-13M$-13M$-9M$1M
Low$-14M$-14M$-11M$1M
High$-11M$-13M$-8M$2M
EPS Avg$-0.28$-0.30$-0.20$0.03
Low$-0.31$-0.31$-0.23$0.02
High$-0.24$-0.27$-0.18$0.04
Analysts (Rev / EPS)2 / 22 / 22 / 21 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$950,000$1M$2M$2M$2M$3M$5M$6M
Low$485,795$1M$1M$1M$2M$2M$4M$4M
High$1M$2M$2M$3M$3M$4M$6M$7M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-5M$-5M$-5M$-5M$-5M$-5M$-3M$-4M
Low$-6M$-7M$-6M$-7M$-7M$-7M$-4M$-5M
High$-4M$-3M$-3M$-3M$-3M$-3M$-2M$-2M
EPS Avg$-0.07$-0.08$-0.07$-0.08$-0.08$-0.08$-0.04$-0.06
Low$-0.08$-0.10$-0.09$-0.10$-0.10$-0.10$-0.05$-0.07
High$-0.06$-0.05$-0.05$-0.05$-0.05$-0.05$-0.03$-0.04
Analysts (Rev / EPS)2 / 21 / 11 / 11 / 11 / 11 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Jun 3, 2026Loop Capital Markets
Lucid Capital Markets Starts Microbot Medical (MBOT) at Buy
Target:$4.00
+99.0%from $2.01
Dec 3, 2025Roth Capital
Microbot Medical initiated with a Buy at Roth Capital
Target:$5.50
+148.9%from $2.21
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.